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INTRODUCTION
Bullous pemphigoid is an autoimmune skin 
disease, characterised by the formation of 
intensely itchy blisters, which largely affects 
older people. Approximately 3500 people 
are diagnosed with bullous pemphigoid 
for the first time in England every year, 
and the diagnosis is associated with 
approximately three-times increased risk 
of death in the first 2 years.1,2 Additionally, 
the diagnosis is associated with increased 
risk of autoimmune conditions (for example, 
systemic lupus erythematosus), neurological 
conditions (for example, Parkinson’s 
disease), cardiovascular conditions (for 
example, hypertension), and other skin 
conditions (for example, psoriasis).3–5 
Oral prednisolone has traditionally been 
the first-line systemic treatment for bullous 
pemphigoid for decades.6,7 In recent years, 
the benefit of safer alternatives has been 
demonstrated including super-potent topical 
corticosteroids and anti-inflammatory 
antibiotics (for example, doxycycline)8,9 but 
systemic steroids are still widely used. 
Although effective, prednisolone exposes an 
already vulnerable group to an increased 
risk of conditions such as osteoporosis and 
diabetes.10,11 Patients may be started on 
moderate-to-high doses of oral prednisolone 
in primary or secondary care settings. 
Patients referred onwards to secondary 
care for diagnosis and treatment of bullous 
pemphigoid typically have their long-term 
management shared jointly between primary 
and secondary care teams. 
Characterising oral prednisolone 
exposure allows us to better understand 
the iatrogenic risks for people with bullous 
pemphigoid. The long-term use in this 
population is poorly understood, and the 
little available evidence is based on small 
studies involving hospital-based patients 
(Table 1).12–22 Routinely collected health 
data from primary care, in the form of the 
Clinical Practice Research Datalink (CPRD), 
provides an opportunity to address this 
research gap using a large population-based 
sample that is broadly representative of the 
UK.23 This study examines prescriptions for 
oral prednisolone issued in UK primary care 
for incident cases of bullous pemphigoid.
METHOD
Study design and data source
This was a prospective cohort study using 
routinely collected health data from the 
CPRD. The CPRD is a longitudinal database 
of UK general practices containing the 
anonymised diagnosis, referral, prescription, 
and vaccination data of approximately 
17 million people, with a current coverage 
of approximately 2.7 million (4%) of the UK 
population. Although bullous pemphigoid is 
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Background
Oral prednisolone is the mainstay treatment for 
bullous pemphigoid, an autoimmune blistering 
skin disorder affecting older people. Treatment 
with moderate-to-high doses is often initiated in 
secondary care, but then continued in primary 
care. 
Aim
To describe long-term oral prednisolone 
prescribing in UK primary care for adults with 
bullous pemphigoid from 1998 to 2017.
Design and setting
A prospective cohort study using routinely 
collected data from the Clinical Practice 
Research Datalink, a primary care database 
containing the healthcare records for over 
17 million people in the UK.
Method
Oral prednisolone exposure was characterised 
in terms of the proportion of individuals with 
incident bullous pemphigoid prescribed oral 
prednisolone following their diagnosis, and the 
duration and dose of prednisolone. 
Results
In total, 2312 (69.6%) of 3322 people with 
bullous pemphigoid were prescribed oral 
prednisolone in primary care. The median 
duration of exposure was 10.6 months 
(interquartile range [IQR] 3.4–24.0). Of 
prednisolone users, 71.5% were continuously 
exposed for >3 months, 39.7% for >1 year, 
14.7% for >3 years, 5.0% for >5 years, and 
1.7% for >10 years. The median cumulative 
dose was 2974 mg (IQR 1059–6456). Maximum 
daily doses were ≥10 mg/day in 74.4% of 
prednisolone users, ≥20 mg/day in 40.7%, 
≥30 mg/day in 18.2%, ≥40 mg/day in 6.6%, 
≥50 mg/day in 3.8%, and ≥60 mg/day in 1.9%.
Conclusion
A high proportion of people with incident 
bullous pemphigoid are treated with oral 
prednisolone in UK primary care. Action is 
required by primary and second care services to 
encourage use of steroid-sparing alternatives 
and, where switching is not possible, ensure 
prophylactic treatments and proactive 
monitoring of potential side effects are in place. 
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predominantly diagnosed in secondary care, 
the diagnosis is subsequently transcribed 
from discharge or specialist clinic letters 
into the CPRD using Read codes.24
For this study only practices recording 
data using VISION software (CPRD GOLD) 
were used. The data in the CPRD have 
repeatedly been shown to be of good 
research quality.25 At the practice level, 
participating practices are audited to 
confirm data quality. At the patient level, 
records are assessed and data checks are 
conducted to ensure that the record meets 
prespecified quality standards. 
This work follows the REporting of 
studies Conducted using Observational 
Routinely collected health Data (RECORD) 
guidelines.26 The data can be requested 
from www.cprd.com.
Study population
The study population comprised adult 
males and females with incident bullous 
pemphigoid diagnoses between January 
1998 and December 2017, selected using 
previously described methods.1,27 In short, 
a validated algorithm was implemented 
to identify people with a code for bullous 
pemphigoid (M145), pemphigoid (M145.00), 
or pemphigoid NOS (not otherwise specified, 
M145z00) in their clinical records. This 
approach has a positive predictive value of 
93.2% (95% confidence interval [CI] = 91.3% 
to 94.8%).27 The bullous pemphigoid index 
date was the date the diagnosis was first 
recorded.
To identify people for whom prednisolone 
might have been prescribed for alternative 
indications, only people with at least 
12 months' data before the bullous 
pemphigoid index data were eligible. In 
order to allow sufficient time to capture 
prescriptions (under the assumption that 
initial treatment would be prescribed in 
secondary care and therefore would 
not appear in the CPRD), people with 
<6 months' follow-up after their bullous 
pemphigoid index date were excluded. 
Observation period
People were followed up from their 
bullous pemphigoid index date until the 
earliest of the date: 1) the person left the 
practice; 2) the person died; 3) the practice 
last contributed data to the CPRD; or 4) 
31 December 2017. 
Oral prednisolone prescriptions
All prescriptions for oral prednisolone (see 
Supplementary Table S1 for Read codes) 
during the observation period were identified. 
This study focused only on prescriptions 
issued after the bullous pemphigoid index 
date based on the assumption that these 
would reflect long-term management 
following the diagnosis. 
Prednisolone dose and duration were 
extracted when available and imputed when 
missing. These data were often missing when 
prescriptions were issued with information 
restricted to the free-text field, such as 
‘Take as indicated by your dermatologist’. 
Implausible and missing values were 
handled using the DrugPrep algorithm,28 
with the decisions described and validated 
by Joseph et al29 (see Supplementary 
Table S2). Cleaning oral glucocorticoid 
prescriptions in this way has been found to 
have a sensitivity of 84.2% (95% CI = 68.7% 
to 94.0%) and a specificity of 87.5% (95% 
CI = 73.2% to 95.8%) for predicting patient-
reported current glucocorticoid use.29
Alternate indications for oral 
prednisolone
Oral prednisolone can be prescribed for other 
indications besides bullous pemphigoid, 
such as rheumatoid arthritis or asthma. To 
understand the proportion of people who 
may have been prescribed prednisolone 
for reasons other than bullous pemphigoid, 
those with a Read code for an alternative 
indication in the 12 months preceding 
their bullous pemphigoid index date were 
identified. The code lists were drawn from 
Kuan et al30 (see Supplementary Table S3). 
Statistical analysis
The proportion of people prescribed 
oral prednisolone following their bullous 
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How this fits in 
Bullous pemphigoid is an autoimmune 
blistering skin disorder that generally 
affects older people and is associated with 
a threefold increase in mortality. Although 
oral prednisolone has been considered 
the mainstay of treatment for decades, its 
long-term use in primary care is poorly 
characterised. This study found that 70% 
of people with incident bullous pemphigoid 
were prescribed oral prednisolone in 
primary care, at considerable doses and 
durations of exposure. As they may be on 
oral prednisolone for prolonged periods 
of time, conversations between primary 
and secondary care physicians involved in 
their care should address steroid-sparing 
alternatives and, when switching is not 
possible, ensure prophylactic treatment (for 
example, bone-sparing treatments) and 
proactive monitoring of side effects are in 
place.
pemphigoid index date was determined. 
The proportion of prednisolone users who 
may have been prescribed prednisolone for 
an alternative indication was determined 
(that is, people with a Read code for an 
alternate indication and a prescription 
for oral prednisolone in the 12 months 
preceding bullous pemphigoid). 
For each prednisolone user, the number 
of prescriptions, total follow-up time, follow-
up time on prednisolone, and proportion of 
follow-up on prednisolone were determined. 
The duration of continuous exposure, defined 
as prescriptions with <15 days between 
the end of one and the start of the next, 
was determined for each patient. The 
number of periods of continuous exposure 
were determined for each patient and 
summarised across the population. The 
proportion continuously exposed for longer 
than 3 months, 1 year, 3 years, 5 years, 
and 10 years were determined. For these, 
the denominator included only people with 
follow-up longer than the duration of interest 
(that is, longer than 3 months, 1 year, 3 years, 
5 years, and 10 years, respectively).
Finally, the doses of oral prednisolone 
were examined. The median daily dose 
for all prescriptions was determined. The 
proportion of prednisolone users prescribed 
≥10 mg/day, ≥20 mg/day, ≥30 mg/day, 
≥40 mg/day, ≥50 mg/day, and ≥60 mg/
day was determined. The cumulative dose 
of prednisolone throughout the whole 
observation period was calculated for each 
patient, and the median determined across 
the population. The average dose while on 
prednisolone was determined by dividing the 
cumulative dose by the duration of exposure. 
A sample size calculation was not 
conducted as this was a descriptive study 
using all available data. Population summary 
measures were presented as the median 
(interquartile range [IQR]) of continuous 
variables or number (proportion) for each 
categorical measure. Analyses were 
conducted with Stata 16. 
RESULTS
Study population
There were 4437 people with incident bullous 
pemphigoid in the study period (Figure 1). 
The 762 people with <6 months' follow-up 
after their index date were excluded from 
the study, of whom 499 died. A further 353 
people without 12 months of data before their 
index date were also excluded. The study 
population therefore comprised 3322 people 
with incident bullous pemphigoid with at 
least 12 months of data before and 6 months 
of data after their index date. They were 
identified from 667 practices, with a median 
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Table 1. Proportion of patients with bullous pemphigoid exposed to oral prednisolone as presented in 
published studies, presented alongside dose and duration information 
     Treatment Patients on oral   
Publication Country Setting Years n timing prednisolone, % Additional dose and duration detail
Balestri et al (2018)12 Italy Clinic 2008–2012 53 Initial 96.2 Dose range: 0.5–0.75 mg/kg/day
Kremer et al (2017)13 Israel Hospital 2008–2014 104 Initial 78.1 Mean dose: 57.3 mg/day (range  
       30–70 mg/day)
Zhang et al (2013)14 China Hospital 2005–2010 94 Initial 85.0 Maximum dose: range 20–80 mg/day
Esmaili et al (2012)15 Iran Hospital 1987-2007 122 Initial 73.8 Mean dose: 60.38 mg/day (SD 21.21,  
       range 5–120 mg/day)
Kulthanan et al (2011)16 Thailand Clinic 1991–2009 58 Initial 89.7 Mean cumulative dose to achieve  
       remission: 0.05 g/kg
Serwin et al (2007)17 Poland Hospital, clinic 2000–2005 35 Initial 68.6 Dose range: 40–60 mg/day
Nanda et al (2006)18 Kuwait Clinic 1991–2005 41 Initial 100 —
Tan and Tay (2018)19 Singapore Hospital 2004–2012 100 Any time  96.0 Mean duration: 11.6 months (range  
       1 week to 60 months)
Wong and Chua (2002)20 Singapore Hospital 1998–1999 59 Initial 76.0 Mean dose: 31.2 mg/day (range  
       15–60 mg/day) when used as 
       monotherapy
Chang et al (1996)21 Taiwan Hospital 1977–1994 86 Initial 83.7 Mean dose: 54.1 mg/day
Garcia-Doval et al (2005)22 Spain Hospital 1998–2003 26 Unclear 53.9 Mean daily dose at start of therapy:  
       34 mg (SD 9.8, range 20–50 mg/day)
       Mean duration: 20 months (SD 12) 
SD = standard deviation.
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of four people with bullous pemphigoid for 
each GP practice. 
The median age at first recording of 
bullous pemphigoid was 79.7 years (IQR 
71.6–86.0) and 1858 (55.9%) were female. 
Median duration of follow-up was 3.1 years 
(IQR 1.5–5.7) and ranged from 6 months to 
18 years. Overall, the population represents 
13 758.2 person–years of follow-up (data not 
shown).
Prednisolone users
Overall, 2312 (69.6%) people were prescribed 
oral prednisolone after their bullous 
pemphigoid index date. They were followed 
for 9506.0 person–years, of which 9.3 
person–years were on prednisolone. The 
median number of months individuals spent 
on prednisolone was 10.6 (IQR 3.4–24.0), 
representing a median of 0.11% (IQR 0.02–
0.24) of their follow-up. The median number 
of prescriptions for prednisolone for each 
patient was 15 (IQR 8–26) (data not shown).
Of the prednisolone users, only 321 (13.9%) 
had complete data for all prescriptions. For 
the remaining patients, the dose, start date, 
or treatment duration were imputed for at 
least one prescription. Eighty-eight (3.8%) 
of the prednisolone users had a Read code 
for an alternate indication (for example, 
rheumatoid arthritis) and a prednisolone 
prescription in the 12 months before bullous 
pemphigoid (data not shown). 
Duration of continuous exposure
The median number of periods of continuous 
exposure for a patient was 2 (IQR 1–3) 
and periods ranged from 1 day to 12 years 
Figure 1. Identification of the study population of adults 
with incident bullous pemphigoid from the CPRD. 
CPRD = Clinical Practice Research Datalink.
People with an acceptable CPRD record
n = 17 029 241
People with a CPRD diagnosis of bullous pemphigoid
n = 7967
People <18 years of age on index date
n = 105
Adults with a CPRD diagnosis of bullous pemphigoid
n = 7862
People with index date outside observation period
n = 3020
Adults with a CPRD diagnosis of bullous pemphigoid
January 1998 to December 2017
n = 4842
People with index date within 12 months of
current registration date
n = 405
People with an incident diagnosis of bullous pemphigoid
January 1998 to December 2017
n = 4437
People with <6 months’ follow-up after bullous
pemphigoid index date
n = 762
People with incident bullous pemphigoid with
≥6 months’ follow-up after index date
n = 3675
People with <12 months’ follow-up prior to bullous
pemphigoid index date
n = 353
People with incident bullous pemphigoid for analysis
n = 3322
duration. Overall, 71.5% of prednisolone 
users were on prednisolone continuously 
for >3 months, 39.7% for >1 year, 14.7% for 
>3 years, 5.0% for >5 years, and 1.7% for 
>10 years (Figure 2). 
Oral prednisolone doses
The median daily dose across all 
prescriptions was 10 mg/day (IQR 5–13). 
There were 1721 (74.4%) prednisolone users 
who were prescribed a maximum dose of 
≥10 mg/day, 941 (40.7%) were prescribed 
≥20 mg/day, 420 (18.2%) ≥30 mg/day, 153 
(6.6%) ≥40 mg/day, 87 (3.8%) ≥50 mg/day, 
and 44 (1.9%) ≥60 mg/day (Figure 3) at any 
point during the observation period. 
The median cumulative dose during follow-
up was 2974 mg (IQR 1059–6456). Focusing 
only on the duration of follow-up where the 
person was on a prednisolone prescription, 
the average daily dose was <2.5 mg/day 
for 11 (0.5%) people, 2.5–5.0 mg/day for 152 
(6.6%) people, 5.0–7.5 mg/day for 351 (15.2%) 
people, and >7.5 mg/day for 1798 (77.8%) 
people (data not shown).
DISCUSSION
Summary
This study explored oral prednisolone 
prescribing for people with bullous 
pemphigoid in UK primary care. Of all people 
with new diagnoses of bullous pemphigoid 
identified from 1998 to 2017, 69.6% were 
prescribed oral prednisolone in primary 
care following their diagnosis. Under the 
assumption that the initial high-dose 
regimens of prednisolone are more likely to 
be issued in dermatology clinics rather than 
in primary care, and ongoing prescriptions 
may not exclusively be issued in primary 
care, these findings likely underestimate 
both the duration of exposure and dosages 
of prednisolone, and should be viewed as 
the minimum exposure. 
This study found that 71.5% of 
prednisolone users were exposed to 
prednisolone continuously for >3 months, 
and 39.7% were on prednisolone for >1 year. 
A small subset (1.7%) were on prednisolone 
continuously for >10 years. Most patients 
(74.4%) received daily doses ≥10 mg/day 
at some point. The prescriptions totalled 
a median cumulative dose of 2974 mg 
throughout the study period and, for 77.8% 
of the patients, an average daily dose 
of >7.5 mg/day during active periods of 
prescriptions. 
Despite this study only presenting the 
minimum estimated exposure, these levels 
are sufficient to place people with bullous 
pemphigoid at risk of corticosteroid-
associated adverse events.31,32 Strict 
monitoring and proactive management 
are required to minimise the risks to this 
population.
Strengths and limitations
Strengths of the present work include a 
large sample size, people with bullous 
pemphigoid identified from a source 
population that is broadly representative 
of the UK,23 and the implementation of 
validated methods for identifying bullous 
pemphigoid and preparing the prescription 
data. The algorithm used to identify people 
with bullous pemphigoid has a positive 
predictive value of 93.2%,27 thus indicating 
that the population analysed likely have 
bullous pemphigoid. The approach to 
preparing the prescriptions is validated and 
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Figure 2. Proportion of prednisolone users continuously 
exposed to oral prednisolone for longer than 3 months, 
1 year, 3 years, 5 years, and 10 years.a 
aThe denominator for duration includes only people 
with follow-up durations exceeding the duration of 
interest.
Figure 3. Proportion of prednisolone users prescribed 
a maximum daily dose of oral prednisolone ≥10 mg, 
≥20 mg, ≥30 mg, ≥40 mg, ≥50 mg, ≥60 mg at any point 
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shown to accurately classify current oral 
corticosteroid status (on/off) for 86% of 
patients.29 Daily dose estimates generated 
from this approach are imprecise but not 
significantly biased, with a mean absolute 
difference in estimated and reported doses 
of 3.2 (standard deviation [SD] 4.2) mg/day.29 
Finally, the authors of the current study 
believe it largely comprises individuals 
who were prescribed prednisolone for 
bullous pemphigoid rather than for other 
indications. Only 3.8% of the prednisolone 
users had: 1) a record for an alternative 
indication for oral prednisolone; and 2) a 
prescription for oral prednisolone in the 
12 months preceding bullous pemphigoid.
Limitations largely relate to the nature 
of the data used. First, although validated 
approaches for identifying patients 
and exposure were used, the findings 
may be subject to misclassification 
and measurement error. This is further 
compounded by the large proportion of 
missing data, affecting at least one 
prescription for 86.1% of people. Second, 
only prescriptions issued in primary care 
could be examined. As a result, it was only 
possible to present the minimum estimated 
exposure to prednisolone. In addition, the 
absence of information regarding the timing 
and duration of secondary care follow-up 
meant that this study could not describe the 
interplay between primary and secondary 
care prescribing of prednisolone. Third, it 
was not possible to capture and describe 
tapering regimens for prednisolone because 
of insufficient granularity in the data. Fourth, 
only oral prednisolone was examined and 
other systemic oral corticosteroids were 
not considered, such as betamethasone, 
and the study may therefore have 
underestimated total corticosteroid 
exposure. Finally, exclusion of people with 
<6 months' follow-up may have limited the 
external validity of the sample as death 
was the commonest reason for insufficient 
follow-up. However, it was felt that including 
people with <6 months' follow-up would 
artificially lower the estimated exposure 
to prednisolone as there was insufficient 
time for the prescriptions to pass from 
dermatology clinics to general practice. 
Comparison with existing literature
To the authors’ knowledge, this is the 
first population-based cohort study to 
examine the prescribing patterns of oral 
prednisolone for bullous pemphigoid in 
UK primary care. Recent evidence on oral 
corticosteroid use for bullous pemphigoid 
in the UK is based on a national audit 
completed by members of the British 
Association of Dermatologists. In this, 
85.5% (n = 448/524) of those with bullous 
pemphigoid diagnoses were prescribed an 
oral corticosteroid by their dermatologist at 
some point during their management.33 The 
current study found that a more modest 
69.6% of people are prescribed prednisolone 
in primary care, although this discrepancy 
may be largely attributed to the different 
settings. The higher proportion from the 
British Association of Dermatologists audit 
suggests that some people are exposed 
to prednisolone only in secondary, and not 
primary, care. It may be that these people 
commence oral prednisolone, which is 
then stopped in favour of an alternative 
treatment, because of disease resolution, 
or death. Alternatively, they may continue 
to be prescribed oral corticosteroids in 
secondary care. 
Worldwide, several studies have reported 
oral prednisolone use in people with 
bullous pemphigoid. The current findings 
are largely in keeping with the proportion 
of prednisolone users in the previous 
literature, although with substantially lower 
doses than elsewhere (Table 1). Again, this 
may be because of differences in the setting 
and timing of prescriptions (that is, initial 
versus long-term treatment). In clinical 
practice, oral corticosteroids are used 
with a slowly reducing regimen for many 
months. Previous studies have captured 
the high initial doses prescribed. This work 
has extended beyond this initial period and 
captured high maximum doses (≥60 mg/
day in some) potentially indicative of initial 
doses and lower maintenance doses (for 
example, median daily doses <10 mg/day), 
potentially reflecting tapering regimens. 
Further interpretation of earlier evidence 
is hindered by the small population sizes 
and the largely hospital-based setting of 
previous research that generally did not 
extend beyond the initial management. 
Implications for research and practice
Those with bullous pemphigoid are a 
clinically vulnerable group because of 
their older age (median age: 79.7 years) 
and significant comorbidities, including 
hypertension, diabetes mellitus, heart 
failure, and osteoporosis.34 There is 
therefore a need for careful consideration 
of additional risks for this population. 
There is evidence of a dose-dependent 
relationship between the cumulative dose of 
prednisolone and sleeping problems, acne, 
skin bruising, mood problems, cataracts, 
hyperglycaemia, and bone fractures.35 
Focusing specifically on fracture risk, a 
daily dose of 7.5 mg/day approximately 
doubles the chance of developing a hip 
and vertebral fracture compared with 
<2.5 mg/day.32 This risk is evident even 
within 3–6 months of starting.31 As such, 
clinicians are exposing people with bullous 
pemphigoid to substantial iatrogenic risks 
as a result of prednisolone prescribing. 
Although these risks are outweighed in the 
short term by the urgent need to control the 
disease, this work shows that the exposure 
to prednisolone extends beyond the initial 
regimens prescribed in dermatology clinics. 
Although GPs will often not be involved 
in the initial aggressive management of 
bullous pemphigoid, they may be tasked 
with prednisolone prescribing in the 
longer term. The authors urge clinicians 
to be mindful that this population, who 
may already be frail because of their age 
and significant comorbidities, may be on 
large doses of prednisolone for substantial 
periods of time. Strict monitoring and careful 
consideration of prophylactic treatments, 
such as bone-protection therapies, are 
essential for their long-term management. 
In addition, conversations between primary 
and secondary care should take place 
to consider steroid-sparing alternative 
treatments such as doxycycline. In 2017, 
doxycycline was shown to be non-inferior 
to oral corticosteroids for the management 
of bullous pemphigoid.8 This will likely have 
an impact on clinicians’ practices, but such 
changes will not have been captured by the 
present work (observation period 1998–
2017). Further research may be needed to 
re-explore systemic steroid prescribing in 
patients post-2017.
Future research should also expand 
on this current study to examine steroid-
related outcomes (for example, hip and 
pelvis fractures) in people with bullous 
pemphigoid, and to determine whether 
adequate monitoring and prescription 
of prophylactic treatment (for example, 
bisphosphonates) occur. 
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